Great piece on stagnation in medicine by Sarah Constantin - regulation + IRBs slow progress with no demonstrated safety increase - funding model tied to rigid plans rather than results - cost of trials incentivize marginal progress over high risk/rewardhttp://reason.com/archives/2018/05/12/when-cancer-was-conquerable …
0 replies
19 retweets
40 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.